Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.63 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632621 | 1.00 | GHSR (0.63) | GHSRIL23RUTS2RNPY1RNPY2R | |
| SCHEMBL29564967 | 0.96 | UTS2R (0.61) | GHSRIL23RUTS2R | |
| SCHEMBL30662387 | 0.96 | IL23R (0.62) | GHSRIL23RUTS2RNPY1RNPY2R | |
| SCHEMBL30276219 | 0.95 | GHSR (0.61) | GHSRIL23RUTS2R | |
| SCHEMBL29364031 | 0.95 | IL23R (0.61) | GHSRIL23RUTS2R | |
| SCHEMBL30276201 | 0.95 | GHSR (0.60) | GHSRIL23RUTS2R | |
| SCHEMBL11206834 | 0.95 | IL23R (0.61) | GHSRIL23RUTS2R | |
| SCHEMBL31514537 | 0.95 | IL23R (0.61) | GHSRIL23RUTS2R | |
| SCHEMBL11206825 | 0.95 | IL23R (0.61) | GHSRIL23RUTS2R | |
| SCHEMBL29366876 | 0.94 | GHSR (0.60) | GHSRIL23RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2025-02-27 | — | — | US | disclosed |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11707540-B2 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230144360-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497822-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885UTS2R 257/4885 |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885UTS2R 257/4885 |
| US-20250064996-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885UTS2R 257/4885 |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885UTS2R 257/4885 |
| US-20230144360-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885UTS2R 257/4885 |
| US-11707540-B2 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | GHSR 661/4885IL23R 107/4885UTS2R 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.